市场调查报告书
商品编码
1471096
精准医疗市场:依技术、应用程式、最终用户、配置- 2024-2030 年全球预测Precision Medicine Market by Technology (Big Data Analytics, Bioinformatics, Companion Diagnostics), Application (CNS, Immunology, Oncology), End-User, Deployment - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年精准医疗市场规模为681.2亿美元,预计2024年将达757亿美元,2030年将达到1,434.3亿美元,复合年增长率为11.22%。
精准医疗是指考虑患者遗传、环境和生活方式的差异,并制定疾病预防和治疗方案的策略。这个概念可以作为癌症、心臟病、囊肿纤维化、糖尿病等的有效预防方法。精准医学用于预测疾病易感性、改善疾病检测并提供量身定制的疾病预防策略。政府正迅速加强改善精准医疗领域的研发活动,同时增加低收入者获得医疗保健治疗选择的机会。製药、软体和生物资讯公司共同努力表征基因,扩大了药物发现。然而,精准医学治疗的报销以及缺乏标准化报销代码和定义阻碍了患者招募和研发工作。此外,FDA 复杂的药物治疗核准流程和随后的商业化挑战也是主要障碍。然而,由于政府和监管机构努力确保基因定序和次世代定序的准确性,监管合规性正在改善。此外,人工智慧、机器学习和云端基础的解决方案的采用使研究人员能够使用电子健康记录中的复杂资料来检测早期疾病,例如阿兹海默症和失智症。
主要市场统计 | |
---|---|
基准年[2023] | 681.2亿美元 |
预测年份 [2024] | 757亿美元 |
预测年份 [2030] | 1434.3亿美元 |
复合年增长率(%) | 11.22% |
科技巨量资料分析推进精准医疗领域
巨量资料分析和生物资讯技术利用实验和电子健康记录中的分子、临床和数数位资料来开发精准医学和治疗方法。伴同性诊断是指用于检测更有可能对精准医学治疗技术做出反应的患者的特定基因突变或生物标记的测试。精准医学利用基因序列测定和次世代定序仪对多个基因进行定序并识别与疾病相关的基因突变,帮助患者获得正确的治疗方法。
应用范例:利用精准医疗进行个人化癌症/肿瘤治疗
在中枢神经系统疾病的治疗中使用精准医学可以促进全面的基因评估、生物标记的识别以及基于患者遗传学的治疗方法修改。透过评估与发炎性肠道疾病(IBD)和全身性红斑性狼疮免疫性疾病相关的生物标记物,可以透过精准医疗有效地针对这些疾病进行治疗。大肠直肠癌、胃癌和肺癌可以透过个人化医疗来治疗,个人化医疗可根据特定组织、基因突变和与每个癌症病例相关的因素提供个人化治疗方法。在呼吸系统疾病中,精准医学用于评估患者是否接受支气管镜和外科手术干预,例如支气管镜肺减容术和肺减容术。
最终用户的研发投资以及生技和诊断公司为推动精准医疗领域所做的努力
主要生物技术和诊断公司从事与个人化癌症治疗和疫苗开发以及药物发现相关的研发活动。不断发展的科学技术进步正在推动精准医学在实验室和医学中的使用,以进行个人化疾病诊断以及随后为患者开发适当的治疗方法。领先的研究中心和政府机构致力于进行研究合作,以揭示心臟病、糖尿病、肥胖症和其他与年龄相关的疾病等常见疾病的原因。
部署:整合人工智慧和云端解决方案,提高精准医疗服务的有效性和开发速度
云端运算和人工智慧的整合创建了基因组云端解决方案,使临床医生即使在偏远地区也能分析大型患者资料集。透过云端平台部署精准医疗解决方案,提高分析效率。使用云端解决方案提前检测阿兹海默症和失智症疾病正在引起人们的注意。本地精准医疗利用 NGS 分析和体学实验产生并储存在机构资料库中的资料。
区域洞察
在美洲,人们对将人工智慧和机器学习整合到精准医疗中以治疗和管理癌症和肿瘤的兴趣日益浓厚。美洲政府的措施正在鼓励临床医生和医生采用精准医学进行治疗。墨西哥和哥伦比亚正致力于分析其公民的整个基因组成,以帮助医疗和研究相关人员做出更准确的医疗决策。在亚太地区,包括印度和中国在内的新兴经济体正在增加对基因疗法研究和开发微型机器人等产品的投资以协助管理。此外,这些国家越来越多的癌症诊所和医院正在使用精准医疗来指南病患的诊断和治疗。日本政府旨在促进医疗记录的协作,包括医学基因组检测资料和个人健康记录(PHR),这可以改善精准医疗和药物开发。在英国、德国和瑞士等欧洲国家,强大的研究机构和学术机构对新颖研究的关注正在推动个人化治疗方法和药物的发展。该地区正在巩固其在生命科学领域的地位,大型製药企业和生物技术公司提供精准医疗解决方案。
FPNV定位矩阵
FPNV定位矩阵对于评估精准医疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对精准医疗市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.精准医疗市场规模及预测是多少?
2.在精准医疗市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.精准医疗市场的技术趋势和法规结构是什么?
4.精准医疗市场主要厂商的市场占有率为何?
5. 进入精准医疗市场的合适型态或策略手段是什么?
[196 Pages Report] The Precision Medicine Market size was estimated at USD 68.12 billion in 2023 and expected to reach USD 75.70 billion in 2024, at a CAGR 11.22% to reach USD 143.43 billion by 2030.
Precision medicine refers to the strategy of tailoring disease prevention and treatment solutions by considering the differences in patient's genetics, environments, and lifestyles. This concept can be utilized as an effective prevention technique for cancers, heart diseases, cystic fibrosis, and diabetes. Precision medicine is used to predict disease susceptibility, improve disease detection, and offer customized disease-prevention strategies. Government efforts to improve research and development activities in the precision medicine sector and simultaneously improve the accessibility of healthcare treatment options for lower-income individuals are increasing rapidly. Joint efforts between pharmaceutical, software, and bioinformatics companies to characterize the genes have expanded drug discovery. However, the lack of reimbursement for precision medicine-based treatment and standardized reimbursement codes and definitions hampers patient adoption and R&D activities. Additionally, the complicated FDA pharmacotherapy approval process and subsequent commercialization challenges of the product pose significant hurdles. However, efforts by government and regulatory agencies to ensure the accuracy of gene sequencing and next-generation sequencing have improved compliance with regulations. Additionally, the adoption of AI, ML, and cloud-based solutions allows researchers to use complex data from electronic health records to detect early-onset diseases, including Alzheimer's and dementia.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 68.12 billion |
Estimated Year [2024] | USD 75.70 billion |
Forecast Year [2030] | USD 143.43 billion |
CAGR (%) | 11.22% |
Technology: Big data analytics is advancing the field of precision medicine
Big data analytics and bioinformatics technologies utilize molecular, clinical, and digital data derived from experimentation and electronic health records for the development of precision medicines and therapies. Companion diagnostics refer to tests used to detect specific genetic mutations and biomarkers in patients who have a higher probability of responding to precision medicine treatment techniques. Gene sequencing and Next-generation sequencing are utilized in precision medicine to sequence multiple genes and identify disease-associated gene mutations to facilitate matching of patients to appropriate therapies.
Application: Personalized cancer and oncology care using precision medicine
Precision medicine for the treatment of CNS disorders can be used to facilitate comprehensive genetic assessment, identifying biomarkers, and modification of treatments according to the patient's genetics. Immune disorders, including Inflammatory Bowel Disease (IBD) and Systemic Lupus Erythematosus, can be effectively targeted by precision medicine by evaluation of biomarkers implicated in these diseases. Colorectal cancer, stomach cancer, and lung cancer can be tackled by utilization of a personalized medicine regime that offers individualized treatment options tailored to specific tissues, genetic mutations, and factors relevant to each case of cancer. For respiratory diseases, precision medicine has been used for the assessment of patients for bronchoscopic or surgical interventions such as bronchoscopic lung volume reduction and lung volume reduction surgery.
End-user: Efforts by biotechnology and diagnostic companies to invest in R&D and advance the field of precision medicine
Major biotechnology and diagnostic companies are developing personalized cancer therapeutics and personalized vaccines and are involved in R&D activities related to drug discovery. Evolving scientific and technological advancements have propelled the utilization of precision medicine in laboratories and pharmaceuticals for personalized disease diagnosis and subsequent development of appropriate treatment regimes for the patient. Major research centers and government institutions are focusing on developing collaborative research to understand the causes of common diseases, including heart disease, diabetes, obesity, and other aging-related morbidities.
Deployment: Integration of AI and cloud solutions to improve efficacy and speed of development of precision medicine services
Cloud computing and the integration of AI have led to the generation of genomic cloud solutions that allow clinicians to analyze larger patient datasets, even in remote settings. Deployment of precision medicine solutions through on-cloud platforms improves the analysis efficiency. The utilization of cloud solutions for the detection of diseases such as Alzheimer's and dementia in advance is gaining attention. On-premise deployment of precision medicine involves the utilization of data generated during NGS analysis and omics experiments and stored in institutional databases.
Regional Insights
Countries in the Americas are increasing the focus on the integration of AI and ML in precision medicine for the treatment and management of cancers and tumors. Government efforts in the Americas has propelled the deployment of precision medicine by clinicians and physicians for treatment purposes. Mexico and Colombia are exerting efforts to analyze the entire genetic constitution of the citizens to better equip medical and research personnel with medical decision-making. In the APAC region, emerging economies, including India and China, are increasing investment in gene therapy research and developing products such as microbots that aim to support precision medicine delivery. These countries are also experiencing a rising number of cancer care clinics and hospitals that utilize precision medicine to guide patient diagnosis and treatment. The Japanese government aims to promote the linkage of medical records, including medical genomic testing data and personal health records (PHRs), which can improve the development of precision medicines and drugs. In the European nations of UK, Germany, and Switzerland, the presence of robust research institutions and focus of academic institutions on novel research is responsible for driving the development of personalized treatment regimes and medicines. The provision of precision medicine solutions by major pharmaceutical and biotechnological companies located in European nations has allowed the region to solidify its position in the life sciences sector.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Precision Medicine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Precision Medicine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AccessDX Holdings, Adaptive Biotechnologies Corporation, Biocrates Life Sciences AG, bioMerieux SA, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Foundation Medicine, Inc., Guardant Health, Inc., healthOme, Illumina, Inc., Intomics by ZS Associates, Inc., Invitae Corporation., Laboratory Corporation of America Holdings, Medtronic PLC, Natera Inc., Novartis AG, Pfizer Inc., Precision Medicine Group, LLC, QIAGEN GmbH, Quest Diagnostics Incorporated, Strata Oncology, Inc., Syapse, Inc., Tempus Labs, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Precision Medicine Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Precision Medicine Market?
3. What are the technology trends and regulatory frameworks in the Precision Medicine Market?
4. What is the market share of the leading vendors in the Precision Medicine Market?
5. Which modes and strategic moves are suitable for entering the Precision Medicine Market?